ISB 1342

DB17251InvestigationalProtein Based Therapies

ISB 1342 is a bispecific antibody simultaneously targeting CD38 and CD3.

Mechanism: Pharmacologically active on ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 and T-cell surface glycoprotein CD3
Curator reviewed
Code names: GBR-1342 · ISB-1342

Resolves to

Compound

Targets

What you can answer from here — as of July 08, 2026

2Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

1Clinical trialPhase, status and sponsor resolved per trial

2+ReferencesStructured and connected to the statements they support

Which drugs share a target with ISB 1342, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.